Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation
| Autor: | Richard A. Grimm, R. Daniel Murray, Amrik Shah, Susan E. Jasper, Steven R. Deitcher, Mohammed Bashir, Allan L. Klein |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Cost-Benefit Analysis medicine.medical_treatment Electric Countershock Low molecular weight heparin Cardioversion Internal medicine Atrial Fibrillation Antithrombotic medicine Humans Thrombolytic Therapy Radiology Nuclear Medicine and imaging Enoxaparin Thrombus Stroke business.industry Warfarin Anticoagulants Atrial fibrillation Heparin medicine.disease Treatment Outcome Anesthesia Cardiology Cardiology and Cardiovascular Medicine business Echocardiography Transesophageal medicine.drug |
| Zdroj: | Journal of the American Society of Echocardiography. 14:200-208 |
| ISSN: | 0894-7317 |
| DOI: | 10.1067/mje.2001.109505 |
| Popis: | An alternative clinical management strategy and cost analysis model is presented for patients with atrial fibrillation of >2 days' duration who may benefit from immediate cardioversion with self-administered low-molecular-weight heparin (enoxaparin) as a bridge antithrombotic therapy to warfarin, after a negative transesophageal echo-cardiography (TEE) screening for thrombus. Assuming no difference in stroke or bleeding rates, our cost minimization model shows that the TEE-guided enoxaparin treatment costs are $1353 lower per patient than an intravenous unfraction-ated heparin approach. Sensitivity analyses for stroke and bleeding reveal that the treatment-cost economic dominance of the TEE-guided enoxaparin approach may be enhanced by an expected improvement in clinical outcome. (J Am Soc Echocardiogr 2001;14:200-8.) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|